Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 2,940 shares of the business's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the sale, the insider directly owned 80,277 shares in the company, valued at approximately $2,786,414.67. The trade was a 3.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Agios Pharmaceuticals Stock Down 1.1%
NASDAQ:AGIO opened at $34.80 on Tuesday. The stock's fifty day moving average is $29.00 and its two-hundred day moving average is $32.12. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -4.89 and a beta of 0.79.
Wall Street Analyst Weigh In
A number of research analysts have commented on the company. Truist Financial upped their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday, December 24th. Bank of America boosted their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, December 24th. Leerink Partners boosted their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, December 26th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, March 22nd. Finally, HC Wainwright boosted their price target on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $42.67.
Read Our Latest Analysis on AGIO
More Agios Pharmaceuticals News
Here are the key news stories impacting Agios Pharmaceuticals this week:
- Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (maintaining a "neutral" rating), signaling modest analyst upside and providing some support for the share price. Article Link
- Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29, 2026 — a standard corporate update that can trigger short-term moves around results but is informational until the release. Press Release
- Neutral Sentiment: Insider sale — Tsveta Milanova sold 3,262 shares at ~$34.71 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting; trade reduces her holdings ~6.5% but was routine and pre-planned. SEC Filing
- Neutral Sentiment: Insider sale — CFO Cecilia Jones sold 3,141 shares at ~$34.71 via a Rule 10b5-1 plan to cover taxes on vested awards; holding reduced ~5.4%. Investors typically view such planned tax-related sales as neutral. SEC Filing
- Neutral Sentiment: Insider sale — Sarah Gheuens sold 2,940 shares at ~$34.71 under a pre-arranged plan to cover tax withholding; position decreased ~3.5%. SEC Filing
- Neutral Sentiment: Insider sale — James William Burns sold 3,280 shares at ~$34.71 via a Rule 10b5-1 plan to cover tax obligations; holdings down ~6.2%. SEC Filing
Institutional Trading of Agios Pharmaceuticals
A number of large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $25,000. Assetmark Inc. increased its holdings in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 362 shares during the last quarter. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals in the first quarter valued at $40,000. First Horizon Corp purchased a new position in Agios Pharmaceuticals in the third quarter valued at $45,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $49,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
